https://www.selleckchem.com/pr....oducts/butyzamide.ht
813 for PFS, and = 0.855 for OS). Among 101 adenocarcinomas, ORRs in patients with high-level and low-level gains (50.0% for both, = 0.049) were significantly higher than those without gains (17.6%), yet survival outcomes for both PFS and OS did not improve. amplification was not associated with greater benefit of nivolumab treatment in patients with NSCLC. Further studies are warranted to prioritize immune checkpoint inhibitors in the treatment regimen for patients with amplification. MET amplification was not associated with greate
Aimer
Commentaire
Partagez
